Treatment
Cetuximab clinical trials
We’re tracking 125 recruiting studies that include Cetuximab, each written for real people, not researchers, below.
Recruiting studies
- NCT07618624Enrolling by invitationPhase 2
Drug combination before surgery for recurrent head and neck cancer
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
Foshan, GuangdongAges 18–75 - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07209111RecruitingPhase 2
Testing Calderasib for advanced solid tumors with KRAS G12C mutation
This trial tests a new drug, Calderasib (MK-1084), for people with advanced solid tumors that have a specific KRAS G12C mutation and aren't getting better with standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT06998069RecruitingPhase 3
Head and neck cancer study for older adults
This trial tests a combination of chemotherapy and immunotherapy followed by radiation for older adults with head and neck cancer. It aims to see if this approach is safe and effective for people aged 65 and older.
Providence, Rhode IslandAges 65 years+ - NCT07468071RecruitingPhase 1/Phase 2
Continuing opnurasib treatment for patients who are benefiting
This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.
Sint-Niklaas, Oost VlaanderenAges 18–100 - NCT07415031RecruitingPhase 2
Long term treatment with adagrasib for solid tumor patients
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
Phoenix, ArizonaAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT07247110RecruitingPhase 1
Study of MK-4716 for people with certain solid tumors
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
New Brunswick, New JerseyAges 18 years+ - NCT06227377RecruitingPhase 1
A new drug for cancers with KRAS G12D mutation
This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT07286149RecruitingPhase 1/Phase 2
Study of MK-1084 plus other treatments for lung cancer
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
Clermont, FloridaAges 18 years+ - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05203172RecruitingPhase 4
Continue encorafenib and binimetinib after prior trial benefit
This study lets people who previously took encorafenib and binimetinib continue those same medicines if they are benefiting and side effects are not severe. It’s meant to help participants stay on treatment safely while the original trial is completed.
Phoenix, ArizonaAges 18 years+ - NCT05504278RecruitingPhase 1
Testing IBI351 with chemotherapy for KRAS G12C lung cancer
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Jilin City, ChangchunAges 18–75 - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT06440902RecruitingPhase 2
New treatments for RAS-changed colorectal cancer using blood tests
This study tests new treatment plans for people with metastatic colorectal cancer whose tumors originally had a RAS mutation but later show no RAS mutation in blood tests. The goal is to see if these treatment changes can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT07535112RecruitingPhase 1
Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06306846RecruitingPhase 2
Radiation and immunotherapy before surgery for head and neck cancer
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–70 - NCT07044921RecruitingPhase 2
Irinotecan liposome combination for advanced colorectal cancer
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
BeijingAges 18 years+ - NCT06988852RecruitingPhase 2
Chemo infusion into liver for colorectal cancer spread
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
Wuhan, HubeiAges 18–75 - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT06590259RecruitingPhase 2
Ablation plus drug therapy for colorectal cancer liver metastases
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
ShanghaiAges 18–75 - NCT07204340RecruitingPhase 1
TLN-372 for advanced KRAS-mutant solid tumors
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Birmingham, AlabamaAges 18 years+
Common questions
- Are there clinical trials studying Cetuximab?
- Yes. Clin2 currently lists 125 recruiting studies that include Cetuximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cetuximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cetuximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cetuximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.